NCT05841238View on ClinicalTrials.gov

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

52

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

September 14, 2023

Study Completion Date

November 13, 2023

Conditions

HealthyObese

Interventions

DRUG

LY3502970

Administered orally.

Trial Locations (3)

32117

LabCorp CRU, Inc., Daytona Beach

53704

LabCorp CRU, Inc., Madison

75247

Labcorp Clinical Research LP, Dallas

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY